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ABSTRACT
Cancer is one of the major causes of death in the world. Discovery of platinum metalbased drugs like cisplatin and carboplatin have proved to be successful in cancer treatment. Due
to subsequent development of resistance, side effects, and fewer toxic effects of these drugs, the
usage of these drugs has been limited. Novel drugs were being synthesized utilizing the
transition metals like ruthenium, osmium, and copper.
In this research, ruthenium metal complexes of the formula HL[RuCl4L2] (where L=
ligand) were synthesized. These ruthenium-based drugs exist in prodrug forms which are
activated into antitumor drugs by means of hydrolysis, redox reactions, or reactions with
biological nucleophiles. In these reactions, ruthenium is reduced to the active Ru(II) form from
its inactive Ru(III) state. In this research work, three ruthenium complexes with different ligands
of varying basicity are synthesized, and their hydrolysis reactions are studied under different pH
values using UV-Visible spectrophotometry at room temperature. The ligands utilized in this
project are imidazole, thiazole, and 1H-1,2,4-triazole. Among these, ruthenium imidazole has
passed the Phase I clinical trials. For the ruthenium-imidazole (RIM) complex and the
ruthenium-thiazole (RTZ) complex, rates of the hydrolysis reaction are determined by fitting the
experimental data to proposed kinetic models for these complexes. The kinetic models proposed
did not help in the determination of the rate of hydrolysis of the ruthenium-triazole (RTrz)
complex as the absorbance trend of the RTrz complex in acidic pH values was opposite to the
trend displayed by the RIM and RTZ complexes indicating a different hydrolysis mechanism for
the RTrz complex.
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The comparative data will aid in better drug design and evaluation of pharmacokinetic
parameters. Future studies on hydrolysis of these complexes at different pH values using HPLC
and NMR spectroscopy might reveal the exact mechanism and may lead to characterizing the
products formed in the hydrolysis process.
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CHAPTER 1: INTRODUCTION
Metal-based drugs are the primary choice among the various drugs available for the
chemotherapy of cancer. A platinum-based drug called cisplatin was the most widely used drug
for treatment of ovarian, testicular, neuronal, and other tumors. The success of cisplatin
increased the interest of many scientists to develop more metal-based anti-tumor drugs. Progress
in this field has led to different kinds of ruthenium complexes being synthesized and studied.
Ruthenium reduces the disadvantages associated with cisplatin such as toxicity and drug
resistance.1 Compounds like ruthenium imidazole (RIM) and ruthenium indazole (RIN) are
already in Phase I clinical trials and they proved to be successful anticancer drugs.2,3 As a further
investigation, we synthesized and analyzed the hydrolysis rate of ruthenium complexes with
different ligands like imidazole, thiazole and 1H-1,2,4-triazole.
The different complexes of ruthenium were analyzed for their hydrolysis profiles under
different pH conditions from pH 4.0 to 9.0 at room temperature. Proposed mechanisms and
interpretation of the kinetics based on the ligand properties are presented.
1.1 Cancer
Abnormal growth of cells due to uncontrolled division of the cells at intractable rates and
the ability of these cells to invade and damage normal tissues of the body is known as cancer.
These cancerous cells can spread throughout the body, and this spreading occurs through blood
and lymph systems. The main cause of this abnormal growth of cells is the damage of DNA
through various genetic factors or environmental mutagens. Based upon the ability of the tumor
to spread to other parts of the body, tumors may be classified as benign and malignant. Of these
two, malignant tumors are actually classified as cancerous growth.4,5,6
1

Benign tumor: These tumors are localized and do not undergo metastasis. They are not harmful
to the body because they do not spread to the surrounding organs or tissues. They can be easily
removed by simple surgery.4,5
Malignant tumor: These tumors actually come under the category of cancerous tumors. They
undergo rapid metastasis and spread the cancer to surrounding tissues and organs, resulting in
abnormal growth of the cells. This type of tumor requires aggressive therapy involving surgery,
radioactive therapy, or chemotherapy, or in some cases a combination of these therapies is
required.6
1.1.1 Types of Cancer
Cancer is classified into several types, and they are named based upon the place of origin
of the cancerous growth.5,7 The following illustrates some of these classifications and their
origin:
Carcinoma: In epithelial cells of skin, digestive tract, glands, and so on.
Leukemia: In the stem cells of bone marrow tissue.
Lymphoma: In lymphatic tissue.
Melanoma: In melanocytes.
Sarcoma: In connective tissues of bone or muscle.
Teratoma: In germ cells.
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1.1.2 Treatment of Cancer

The treatment of cancer may be done by a single method or a combination of methods.
The treatment mainly depends upon the type and location of the cancer. If the disease has spread
to other parts of body, a combination of the following methods is more effective.5,6

Surgery is one of the cancer treatment methods that remove cancer. This is the most
common way to treat cancer. It is very rare that the cancer will spread during the surgery.

Radiotherapy is a treatment that uses high energy radiation to kill cancer cells in the
affected area. The advantage of this treatment method is that it is relatively painless.

Chemotherapy is a method of killing cancer cells using drugs. However, it may also harm
the healthy cells. The body will start to produce normal cells after the chemotherapy is over.

Hormone therapy is a method that uses an antagonist to prevent the production of other
hormones needed for cancer cell growth or uses drugs to stop the production of some hormones.
In some cases it might require removal of the hormone-producing organ to prevent secretion.

Side effects of these treatments include terrible pain, nausea, temporary fatigue, and
vomiting.

1.1.3 Drugs Available for Treatment of Cancer

The anticancer drugs can be classified into various types based upon their chemical
structure or based upon their biochemical mechanism. Alkylating agents and antimetabolites are
the drugs most widely used to treat different forms of cancer. The metal-based drugs, mainly the
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platinum complexes, especially cisplatin, which are classified under the alkylating agents, are
often used as the first line of treatment in testicular and ovarian cancers. These drugs bind to
DNA and form adducts which block the synthesis of DNA and RNA, thereby inducing cell
death. Side effects like nephrotoxicity, neurotoxicity, ototoxicity, alopecia, and development of
resistance restricts the usage of the platinum complexes.6,8,9,10

1.1.4 Molecular Mechanism of Action of Antitumor Drugs
Cisplatin is the most widely used drug for treating metastatic testicular and ovarian
tumors. The three main components involved in the antitumor activity by metal-based drugs
include the metal-based drug, DNA, and HMG-protein.11
The drug cisplatin is mainly transported into the cancer cell through active transport.
Sometimes it may occur through passive transport. After entering into the cell, cisplatin forms
adducts with two consecutive guanine bases of DNA. The chloride ions of cisplatin are displaced
by the nitrogen bases of DNA. This is due to the greater affinity of cisplatin for nitrogen bases
compared to its affinity for chlorine. Adduct-induced DNA bending allows the binding of
proteins with the highly mobile HMG domain. Once protein is bound to DNA, it inserts a wedge
like phenyl group of phenylalanine into the adduct. The tightly bound HMG protein causes the
destacking of nucleotide bases, resulting in the inactivation of the DNA helix. With the HMG
protein bound to DNA, the modified strand cannot be repaired and hence the cell dies.11
1.2 Ruthenium

Ruthenium can be considered to be a good alternative to platinum because of its wide
range of oxidation states that are accessible under normal physiological conditions. The activity
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of many anticancer drugs is dependent upon their oxidation states, and hence ruthenium is an
excellent choice. The synthetic versatility, ability to change ligand affinities, high selectivity, and
ability to mimic iron in binding to various biomolecules make ruthenium a viable alternative in
anticancer drug development studies. The first ruthenium compound to be tested for its antitumor
activity, ruthenium imidazole, was developed by M. Clarke.12
Ruthenium exists in two forms; one is the inactive Ru(III) form and the other is the
active, reduced Ru(II) form. Generally ruthenium complexes tend to remain in the Ru(III)
inactive form. Upon reaching the tumor site, ruthenium is reduced to the potent and active Ru(II)
state, which is selectively toxic to tumor cells. This reduction is favored by the environment
surrounding the cancer cell which has a lower pH and low oxygen content than the healthy
tissue.1,12 Like platinum complexes, ruthenium complexes exhibit antitumor effects, inhibiting
the synthesis of DNA and RNA, by forming DNA adducts.13,14

1.2.1 Ruthenium Complexes Used in this Study

The compounds used for this study were imidazolium trans-bis(imidazole)
tetrachlororuthenate (III) {HIm[trans-RuCl4(im)2]} (RIM), which has passed the Phase I clinical
trials; thiazolium trans-bis(thiazole) tetrachlororuthenate (III) {HTz[trans-RuCl4(Tz)2]}(RTZ);
and 1H-1,2,4-triazolium trans-bis(triazole) tetrachlororuthenate (III) {HTrz[trans-RuCl4(Trz)2]}
(RTrz). These compounds are shown in Figures 1 through 3.

5

Figure 1. Chemical structure of HIm [trans-RuCl4(Im)2]

Figure 2. Chemical structure of HTz [trans-RuCl4(Tz)2]
6

Figure 3. Chemical structure of HTrz [trans-RuCl4(Trz)2]

1.3 Hydrolysis

The mechanism of this hydrolysis reaction involves the displacement of a ligand by a
molecule of water. This ligand displacement is important because ruthenium complexes become
activated by this process.

1.4 Kinetics of Hydrolysis and its Importance in Cancer Studies

The study of the rates of chemical reactions is called kinetics. The kinetics can be studied
in various ways including changing various conditions such as concentration and pH. The metalcontaining antitumor drugs are usually in their inactive prodrug form and they become reduced
to their active form by means of hydrolysis. The time taken for the conversion of a prodrug into
an active drug is important in cancer studies because it determines the onset of action, duration
of action, and the clearance rate of drugs.7,15 These kinetic studies will aid in the development of
drugs with enhanced stability, increased potency, and activity.
7

Ruthenium complexes exist in prodrug form, before they are injected into the body. They
are activated into the active Ru(II) form by changing their coordination. Then they react with the
biomolecules and exert their therapeutic activity. This activation can be achieved through various
reactions, such as hydrolysis, involving formation of aqua complexes, ligand substitution, and
redox processes.1,7,15 Hydrolysis is important, as proven with cisplatin, because the prodrug is
activated by means of formation of aqua complexes through hydrolysis. Aqua complexes are
orders of magnitude more labile than chloro complexes resulting in more active compounds.7,15

The ruthenium (III) complexes of the general formula HL[RuCl4L2], contain two trans
bonding heterocyclic ligands L bound to ruthenium via nitrogen. The possible mechanism of
hydrolysis of ruthenium complex bound with heterocyclic ligands is shown in Figure 4. Initially
one or two chloride ions are substituted with water molecules, and then the resulting ruthenium
complexes bind to each other, forming polynuclear complexes. These polynuclear complexes
bind to DNA, forming adducts, and thereby exert their antitumor activity.16

Figure 4. Possible mechanism of hydrolysis of ruthenium complex anion trans-[RuCl4L2]
(Figure from J. of Inorg. Biochem. 2004, 98, 402-412).17
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Bouma et al. suggested two possible transformations of NAMI-A, imidazolium transtetrachloro (dimethylsulfoxide) imidazoleruthenium (III) {H2Im [trans-RuCl4(DMSO-S)HIm]},
a ruthenium complex, in Phase I clinical trials of a cancer study. Initial transformation includes
the ligand substitution, which depends upon the buffer pH and further transformation including
the substitution of ligands or reduction of Ru(III). In acidic media of pH less than 6, the
decomposition of NAMI-A follows pseudo first order kinetics. At pH values greater than or
equal to 6, it follows zero order kinetics. The complex tends to be most stable at a pH of 3-4.16, 17
Velders et al. in search of new ruthenium (III) complexes having a better pharmacological
profile, synthesized the pyrazole, thiazole, and pyrazine analogues of NAMI-A. These
compounds showed a better onset of action than the NAMI-A.18
Mura et al. studied the stability and hydrolysis of thiazolium trans-tetrachlorobis
(thiazole) ruthenate (III) complex in different solvents at different pH values. In previous studies
of NAMI-A with the less basic ligand-thiazole, a significant decrease in the rate of chlorine
exchange with water molecules was observed. The increase in half life of the hydrolysis,
compared to NAMI-A, indicates the stabilizing influence of thiazole on the hydrolysis of
ruthenium (III) complex due to replacement of imidazole with the less basic thiazole ligand.19
Messori et al. conducted studies on hydrolysis of another ruthenium (III) complex,
aminothiazolium trans-tetrachlorobis (aminothiazole) ruthenate (III), in different solvents of
varying pH values.20 Upon comparing different nitrogen-based ligands, these studies indicate
that the more basic the heterocyclic ligand of the ruthenium complex is, the higher the rate of
hydrolysis. The higher electron transfer from the nitrogen to the metal in the ruthenium complex
increases the dechlorination rate by weakening the metal–chloride bond.7,21,22
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Keppler et al. analyzed the ruthenium (III) complex, 1H-1,2,4-triazole [trans-tetrachloro
ruthenate(III) triazole(DMSO)] for the rate of dechlorination and compared it with RIM and RIN
complexes. Studies proved that the greater electron donor character of neutral ligands and the
basicity of azole ligand will promote solvolytic dechlorination, which in turn reduces Ru(III) to
Ru(II).22 In my present research, nitrogen-based ligands of varying basicity were used, and an
attempt was made to determine the effect of basicity of these ligands on the hydrolysis of the
ruthenium (III) complexes, which might support or oppose the theory proposed by Keppler et al.
Based upon the studies conducted by different researchers, ruthenium complexes with
enhanced activity and potency can be developed. According to Messori et al. hydrolysis of the
thiazole complex was found to be fastest when the compound was dissolved in a buffer of pH 7.4
compared to other pH levels.19 Arion et al. proved that decreasing the basicity of ligand
significantly reduces the reduction rate of Ru(III) to Ru(II), thereby limiting the accessibility of
the ligand to interact with the tissues. This process does not allow hydrolysis until the drug
reaches its final target.18,22
1.5 Research Goal
The main theme of this research was to study the effect of various ligands (L=imidazole,
thiazole, 1H-1,2,4-triazole) on the hydrolysis of the ruthenium(III) complexes of general formula
HL[trans-RuCl4L2] at room temperature in buffers of varying pH values. This study will allow a
comparison of the kinetics of the RIM complex, which already passed the Phase I clinical trials,
with the other ligands by determining their respective rate constants of hydrolysis reaction.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
2.1 Instrumentation
A Perkin Elmer Lambda-25 Ultraviolet-Visible spectrophotometer was coupled with a
Perkin Elmer temperature controller to analyze the kinetics of the hydrolysis of ruthenium
compounds. The pH of buffer solutions was measured using a Hanna 8417 pH meter.
2.1.1 UV-Visible Spectrophotometer

The ultraviolet-visible (UV-Vis) spectrophotometer is an instrument that analyzes the
absorbance of compounds in the ultraviolet and visible regions of the electromagnetic spectrum.
Unlike infrared spectroscopy which detects vibrational motions of molecules, ultraviolet-visible
spectroscopy detects electronic transitions. The basic principle in analyzing the absorbance by
UV-Vis spectrophotometer is the Beer-Lambert law. This law states that the absorbance of a
solution is directly proportional to the concentration of solution:
A=€bc
where,
A = absorbance of the solution
€ = molar absorptivity coefficient
c = concentration
b = path length
In general, a hydrogen or deuterium lamp is the light source for the ultraviolet region
from 250-400 nm, and a tungsten or halogen lamp is the light source for the visible region of
400-800 nm. The solvent and sample solutions are placed in the reference and sample cells,
respectively. Monochromatic light from the source is allowed to pass through the cells, and the
11

transmitted light is measured by a detector.23 The basic design of a UV-Vis spectrophotometer is
illustrated in Figure 5.
Ultraviolet and visible light are energetic enough to promote valence electrons to higher
energy levels. UV-Vis spectroscopy is usually used for inorganic ions or complexes in solution
because of their strong absorptions. The UV-Vis spectra have broad features that do not limit
their use only for sample identification but are also very useful for quantitative measurements.
The electronic transitions that are detected by the UV-Visible spectrometer result in
absorption maxima in the spectra, which occur due to the excitation of valence electrons of a
compound from the ground level to higher energy levels. In other words, it can be described as
the excitation of electrons from bonding and nonbonding orbitals to the antibonding or
nonbonding orbitals.23

Figure 5. Schematic representation of UV-Visible spectrophotometer.
2.2 Materials
Ruthenium (III) chloride hydrate (Reagent plus, Sigma Aldrich), imidazole (99%,
Aldrich), thiazole (96% Aldrich), 1H-1,2,4-triazole (97% Aldrich) were used as purchased for
the preparation of ruthenium complexes. Monosodium phosphate hydrate (NaH2PO4.H2O)
12

(Analytical reagent, Mallinckrodt), disodium phosphate hydrate (Na2HPO4.H20), citric acid
(C6H8O7) and sodium chloride (NaCl) (Certified A.C.S, Fischer) were used for the preparation of
buffers.
Synthesis:
Synthesis of HIm[trans-RuCl4(Im)2]: In a mixture of 25.00 ml of ethanol and 25.00 ml of 1.00
N HCl, 1.00 gram of RuCl3 was dissolved. This mixture was refluxed for three hours, and the
resulting solution was evaporated to 9.00 mL. The final volume of the solution was made to be
12.00 mL with 1.00 N HCl. Next, a suspension is prepared by adding 2.00 grams of imidazole to
1.00 mL of 6.00 N HCl, into which 10.00 mL of the ruthenium solution prepared above was
added. Then the solution was cooled in ice for two hours and allowed to stand for two days at
room temperature. The large brownish red crystals formed were filtered off and washed with 1:1
water and ethanol mixture to remove impurities, and dried under vacuum.22,24
NH

S

RuCl3 + 3

N

Imidazole

HCl
C2H5OH

H
+
N

N
Cl

-

Cl

Ru

Cl

Cl

N
H

N
N
H

Figure 6. Synthesis of Ruthenium-Imidazole Complex.
Synthesis of HTz[trans-RuCl4(Tz)2]: 1.00 grams of Ruthenium chloride was dissolved in 10.00
mL of ethanol and 10.00 mL of 1.00 N HCl and refluxed gently for 90 minutes. A solution of
1.92 grams of thiazole dissolved in 2.00 mL of ethanol and 2.00 ml of 6.00 N HCl was added to

13

the ruthenium solution with continuous stirring. The solution was refluxed gently for 30 minutes,
forming a precipitate. Then the brownish red microcrystals were separated by filtration, washed
with ethanol and ether, and dried under vacuum.19
S

S

3

+

N

HCl
Cl

+ RuCl3

NH

Cl
Ru

C2H5OH

Cl

Cl

N

N

S

S

Thiazole

Figure 7. Synthesis of Ruthenium-Thiazole Complex.
Synthesis of HTrz[trans-RuCl4(Trz)2]: 1.00 grams of ruthenium chloride was added to 2.00
grams of 1H-1,2,4-triazole and refluxed for about two hours. The solution was filtered to obtain
large orange crystals of ruthenium triazole complex. The isolated crystals were washed initially
with ethanol and later with diethyl ether to remove the impurities and finally dried under
vacuum.22,26
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+
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Cl
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Figure 8. Synthesis of Ruthenium-Triazole Complex.
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Phosphate buffers: Buffers of pH 4.0, 5.0, 6.0, 7.5, and 9.0 were prepared by using appropriate
volumes of 50 mM monosodium phosphate and 50 mM disodium phosphate and 100 mM
sodium chloride in distilled water. Small amounts of 10% citric acid and 10% sodium hydroxide
solutions were used to adjust the pH of each buffer to the desired value.
2.3 Hydrolysis Kinetics Study

All complexes were found to be significantly soluble in water, making a comparative
kinetic study possible. The complexes were dissolved in freshly prepared buffers, and their
absorbances were recorded over time using the Perkin Elmer Lambda 25 UV-Vis
spectrophotometer. During analysis of the complexes in various pH solutions, the initial
concentration of the complexes was kept constant. For example, in all buffer systems of pH
values 4.0 to 9.0, the concentration of RIM complex was initially 0.050 M. This enables a
comparison of the data due to similar initial concentration of the complex throughout the
analysis.
The following steps were followed in preparation of the sample and analysis of
hydrolysis of the

RIM complex:

1. 2.25 grams of RIM complex were weighed into a 150 mL beaker.
2. 100 mL of water containing phosphate buffer was added to dissolve the RIM complex.
3. The solution was mixed for approximately one to three minutes until a clear and light redcolored solution was obtained.
4. The solution was transferred to a sample cuvette and the reference cuvette was filled with
blank solution containing phosphate buffer of the corresponding pH being investigated.
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5. Then the kinetic analysis was initiated. The pH of the mixture was recorded before initiation
of the analysis. The spectrophotometer was connected to a temperature bath to maintain a
temperature of 25oC ± 1oC. There was a delay of approximately 2-3 minutes between mixing
and initiation of the kinetic run. The absorbance was recorded at a determined wavelength for
approximately six hours, and the final absorbance was measured after a day to allow the
reaction to reach completion.
6. At end of reaction, the pH of the reaction mixture was recorded.
The pH meter was calibrated using standard buffer solutions of pH 7.0 and 4.0 containing
monobasic sodium phosphate and dibasic sodium phosphate. During these studies, the ratio of
masses of ruthenium complex and water was generally maintained around 1:100. The initial
concentration of the complexes was maintained constant in all buffer solutions (0.050 M for
RIM, 0.045 M for RTZ, and 0.010 M for RTrz) during the kinetic runs.
The solutions of RIM and RTZ complexes were clear when initially prepared, but they
gradually become turbid over time during analysis. This turbidity may be due to a precipitation
reaction. Due to the gradual precipitation, these solutions exhibited increasing absorbance over
time.
In acidic pH, the solution of RTrz complex was hazy during the initiation of kinetic run.
But the solution became clear during the analysis. The RTrz complex solution in basic pH was
initially clear but became turbid over time. The turbidity in the solutions of all the complexes
was anticipated due to the precipitation occurring in solution. Both the solution and precipitate
were analyzed using NMR spectrometry, but the paramagnetic nature of ruthenium made it
difficult to characterize the product being formed.

16

It should be noted that there might be certain inconsistencies occurring in the initial
absorbance readings and the concentrations based upon factors including mixing time needed for
a given complex to dissolve in the solution of a particular pH and the time delay between the
actual dissolution of the complex and initiation of the kinetic study. The reaction for a given pH
buffer was run several times and the best two or three trials were used to determined the average
rate constant.
Absorbances were analyzed over a wavelength range of 300-700 nm. Wavelengths
selected for studying the kinetics of the hydrolysis reaction were based upon maximal changes in
absorbance of hydrolyzed complexes. The wavelengths used are 340 nm for RIM, 365 nm for RTZ, and
360 nm for RTrz. Hydrolysis studies were done at pH values of 4.0, 5.0, 6.0, 7.5, and 9.0. All
reactions were studied at room temperature, 25oC±1oC. Analysis of data for the kinetic studies
was performed using the Graphical Analysis program from the Vernier software data analysis
package.
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CHAPTER 3: RESULTS and DISCUSSION
3.1 Mechanism of Kinetics of Hydrolysis of Ruthenium Complexes

The general mechanism of the hydrolysis of ruthenium complexes is proposed to involve
two steps, the formation of intermediate from the reactant and the formation of the final product
from the intermediate. The theory behind the calculation of the kinetic equation to describe this
process involves the classical Arrhenius theory. The two steps of hydrolysis of ruthenium
complexes can be shown as follows:

k1
R

k2
I

P

As shown in the above reaction, the hydrolysis of ruthenium complexes is proposed to
follow a two-step reaction. The reactant (R) converts into an intermediate (I), the substituted
complex with water molecules or hydroxide ions. The second step involves the formation of final
product (P), polynuclear complexes formed due to the combination of substituted ruthenium
complexes. The rate constants of the two steps are denoted as k1 and k2, respectively.
The kinetics for this mechanism can be modeled by solving the differential equations
involving the concentrations of the reactant [R] , intermediate [I], final product [P] and initial
concentration of reactant [R]0 by equations shown below:7,27
[R] = [R]0 e-k1t

(1)

[I] = (k1 [R]0 / (k2-k1))* (e-k1t – e-k2t)

(2)
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[P] = [R]0 – [R] – [I] = [R]0 * {1+[(1/(k1-k2)) * (k2e-k1t – k1e-k2t)]}

(3)

In all of the equations (1), (2), and (3), the concentrations of reactant, intermediate, and
product are functions of time. These equations were used to determine the rate constants. Beer’s
law relates concentration to absorbances in order to determine the kinetic rate constants for these
models.
3.2 RIM and RTZ Complexes

As stated previously, the hydrolysis follows a two-step reaction. The formation of an
intermediate (I) from the reactant (R) is the first step, followed by the formation of product (P)
from the intermediate as the second step. The respective rate constants for the first and second
steps are denoted by k1 and k2, respectively.
In both of these complexes, an induction period was observed in the absorbance spectrum
at all acidic pH levels. This induction period was assumed to be due to the formation of
intermediate. The induction period was found to decrease as the pH is increased. At basic pH
levels, this period was reduced to less than 20 minutes, indicating that higher pH levels caused a
faster formation of the intermediate.
Utilizing absorbance of the complexes instead of concentrations in equations (1) to (3),
the rate constants of the two steps can be calculated as discussed below. The absorbance for each
species is given by the equations (4) – (6), which were derived from solving the proper
differential equations.
AbsR = A e-k1t

(4)
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AbsI = C (k1/ (k2-k1)) (e-k1t – e-k2t)

(5)

AbsP = E (1 + 1/(k1 – k2)) (k2e-k1t – k1e-k2t)

(6)

The total absorbance (AbsT) is obtained by summing the absorbance of the reactant
(AbsR), intermediate (AbsI), and product (AbsP). These absorbances can be related to the rate
constant (k1) of the first step as given in equation (7).
AbsT =

AbsR + AbsI + AbsP

AbsT = Ae-k1t + C (k1 / k2-k1) (e-k1t –e-k2t) + E (1+ (1/k1-k2) (k2e-k1t - k1e-k2t))

(7)

The constants A, C, and E are related to the initial concentration of reactant and the molar
absorptivities of the reactant, intermediate, and product, respectively. The term k1 is the rate
constant of the first step of the reaction, and k2 is the rate constant of the second step of the
reaction. The time for the reaction is given by t.27
The experimental data were fit at long times using equation (8) to find k2. This assumes
that all the reactant has turned into intermediate for these long times. To obtain k2, the latter
exponential part of the curve was fit to the model using equation (8) after 100 minutes.
AbsT = AbsI + AbsP
AbsT = C (1-e (-k2t)) + E e (-k2t).

(8)

3.2.1 Imidazolium trans-tetrachloro bis (imidazole) ruthenate(III) Complex (RIM)
The normal absorbance spectra of RIM, illustrated in Figure 9, display two distinct
maxima at 340 nm and 400 nm. These two peaks are always observed during the study in all
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buffer solutions of different pH values. During hydrolysis, the increase over time for absorption
at 340 nm is greater than the increase at 400 nm in every trial as shown in Figure 10. Due to a
greater increase in absorption at 340 nm, this wavelength was used for the kinetic analysis of
hydrolysis of this complex.

Figure 9. The normal absorbance spectrum of RIM at a pH of 6.0. Two absorbance
maxima at 340 nm and 400 nm are observed.
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Figure 10. Absorbance spectrum of RIM at a pH of 6.0 over time.
Figure 10 indicates an increase in the absorbance of the RIM complex at 340 nm and 400
nm with time. It clearly indicates that the increase in absorbance at 340 nm is higher than the
increase in absorbance at 400 nm.
Based upon the observed absorbance spectra, hydrolysis studies on the RIM complex
were conducted at 340 nm at pH values varying from 4.0 to 9.0. The graphs in Figure 11 through
Figure 14 show how absorbance of the RIM complex at 340 nm at pH values of 4.0, 5.0, 7.5, and
9.0 changes over time.
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Figure 11. The absorbance of RIM complex monitored at 340 nm at a pH of 4.0 for 6 hours.
Equation (7) was used for the best fit on curve before 100 minutes and best fit of
of the curve after 100 minutes was obtained by using equation (8).
Figure 11 reveals an initial induction period of 120 minutes during which the
intermediate is formed. After the induction period, the rate is governed by the second step, the
formation of product from the intermediate. Equation (8) was used to fit the curve after 120
minutes and k2 was determined. The rate constant k1 was then determined using equation (7),
which gives the best fit for first part of the curve. The average rate constant for a pH of 4.0 for
the first step (k1) was 0.02881 sec-1, and the rate constant of the second step (k2) was 0.003510
sec-1. It should be noted that the absorbance was measured a day later, was monitored for a few
hours, and was found to be constant indicating that the reaction had reached completion.
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Though the previous kinetics models proposed were used in determining rate constants,
another possible mechanism known as crystal growth may better explain the slower induction
period and rapid increase in absorbance in Figure 11, as proposed by Dr. Larry Kolopajlo.29 The
absorbance increase could be due to the increased turbidity in the solution over time. The
turbidity is caused by the precipitation of polynuclear complexes in the solution. Further studies
must be done in order to confirm whether the precipitate consists of crystals of polynuclear
complexes. The first step of crystal growth is nucleation, which is known to be brief. The second
step of crystal growth is rapid and evidenced by the increase in turbidity, resulting in a sharp
absorbance increase. The crystal growth mechanism seems suitable for all the complexes
showing an induction period followed by a rapid increase in absorbance.

Figure 12. The absorbance of RIM complex monitored at 340 nm at a pH of 5.0 for 5 hours.
Equation (8) was used for the best fit on curve after 100 minutes.
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Figure 12 clearly indicates that there is an initial induction period of 80 minutes, followed
by a sharp increase in absorbance. The average rate constant for k2 of the data at a pH of 5.0 was
0.004596 sec-1 by fitting equation (8) to the curve after 100 minutes. The rate constant (k1) was
0.02061 sec-1.
The induction period that was clearly observed in graphs at acidic pH levels was found to
diminish as pH increased. Figure 13 shows the hydrolysis profile of RIM complex in a buffer
solution of pH 7.5. At this pH level, the time taken for nucleation reduces to less than an hour.

Figure 13. The absorbance of RIM complex monitored at 340 nm at a pH of 7.5 for
5 hours. Equation (8) was used for the best fit on curve after 100 minutes.
The average rate constant for k2 at pH 7.5 was 0.006331 sec-1, and the rate constant (k1)
was determined to be 0.04145 sec-1.
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Figure 14. The absorbance of the RIM complex monitored at 340 nm at a pH of 9.0 for 6
hours. Equation (8) was used for the best fit on curve after 100 minutes.
At a pH of 9.0, the induction period was observed to shorten to 20 minutes as shown in
Figure 14. This is consistent with a faster formation of the intermediate at higher pH levels. The
average rate constant k2 at this pH was 0.006693 sec-1, and the rate constant k1 was 0.04289 sec1

.
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The rate constants of the two steps of hydrolysis are shown in Table 1. Based upon the
results obtained, it can be hypothesized that the hydrolysis of RIM is a two-step process, and the
rate of the first step increases at basic pH levels as evidenced by an increase the in value of k1.
Table 1. Average rate constants for two steps (k1= first step, k2 = second step) of hydrolysis
of 0.050 M RIM complex at different pH values:

pH

4.0

5.0

k1 for all trials
(s-1)
Trial 1
Trial 2
Trial 3
Trial 1
Trial 2

0.01065
0.02650
0.04973
0.02358
0.02071

Trial 3

0.01754

Trial 1

0.02101

6.0

7.5

9.0

Average k1
(s-1)

0.02881

0.02061

k2 for all trials
(s-1)
Trial 1
Trial 2
Trial 3
Trial 1
Trial 2

0.003794
0.003431
0.003157
0.004778
0.002830

Trial 3

0.006180

Trial 1

0.005526

0.01917
Trial 2
Trial 1
Trial 2
Trial 3
Trial 1

0.01734
0.04515
0.03743
0.04176
0.03163

Trial 2

0.05462

Trial 3

0.04342

0.04145

0.04289

Average k2
(s-1)

0.003510

0.004596

0.004544
Trial 2
Trial 1
Trial 2
Trial 3
Trial 1

0.003545
0.005275
0.009984
0.003727
0.007976

Trial 2

0.005990

Trial 3

0.006114

0.006331

0.006693

All these values of rate constants have been verified with the Q-test for statistical analysis.
For example, at pH = 4.0, trial 3 has a high value, but according to the Q-test used for identifying
statistical outliers, it cannot be discarded because the calculated Q-value for the data is 0.59. To
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disregard a point with three trials, the Q must be greater than 0.94. Thus, the data for the trial 3
cannot be discarded.
Table 1 indicates that rate constant of the first step of the reaction tends to decrease from
the pH values of 4.0 to 6.0 and then starts to dramatically increase at higher pH levels in the
range from pH 7.5 to 9.0. The dramatic increase might be due to the higher reactivity of RIM
complex with phosphate buffer in basic pH values, resulting in the formation of a ruthenium
phosphate complex.29
The rate constant of the second step of the reaction shows a different pattern, increasing
steadily from pH 4.0 to 9.0. For all pH levels at room temperature, the rate of the first step was
found to be almost 10 times faster than the rate of the second step. At higher pH values, k1 and k2
increased dramatically, indicating that the complex might be following a different mechanism at
these pH values. It is proposed that at high pH’s the complex reacts with the phosphate buffer.29
The comparison of the rate constant k2 at different pH values is depicted in Figure 15.
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Figure 15. Comparison of k2 values of the RIM complex at different pH values.
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3.2.2 Thiazolium trans-tetrachlorobis (thiazole)ruthenate(III) Complex (RTZ)

The absorbance spectra of the RTZ complex showed in Figure 16 displays two
absorbance maxima at 365 nm and 420 nm.
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Figure 16. Absorbance spectrum of RTZ complex at a pH of 6.0 over time.
The absorbance spectrum of RTZ complex dissolved in pH 6.0 buffer, shown in Figure
16, clearly indicates a change in the absorbance over time at 365 nm, while the absorbance at
420 nm remains constant. Hence, the study of kinetics of the hydrolysis of RTZ complex was
conducted at 365 nm.
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Using the wavelength of 365 nm, the kinetics of the RTZ complex was analyzed at
various pH values. The graphs in Figures 17 through 20 show the absorbance change of the RTZ
complex in buffer solutions of pH of 5.0, 6.0, 7.5, and 9.0 during the time of the reaction.

Figure 17. Absorbance of RTZ complex monitored at 365 nm at a pH of 5.0 for 12 hours.
Equation (7) was used for the best fit curve before 100 minutes. The best fit of
the curve after 100 minutes was obtained by using equation (8).
In Figure 17, an induction period of 100 minutes is observed to fully form the intermediate,
followed by the second step of the hydrolysis reaction. The average rate constant of the first step,
corresponding to the induction period, was 0.03403 s-1, and average rate constant of the second
step, corresponding to the curve at longer times, was found to be 0.003601 s-1.
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Figure 18. Absorbance of RTZ complex monitored at 365 nm at a pH of 6.0 for 7 hours.
Equation (8) was used for the best fit curve after 100 minutes.
In Figure 18, the induction period was observed for a longer time of about 130 minutes
and followed by the production of product. The average rate constant for k2 was 0.006053 s-1.
The average rate constant for k1 was 0.02391 sec-1.
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Figure 19. The absorbance of RTZ complex monitored at 365 nm at a pH of 7.5 for 8 hours.
Equation (8) was used for the best fit curve after 100 minutes.
The decrease in the induction period is clearly observed in the absorbance spectrum of
the RTZ complex at a pH of 7.5, as shown in Figure 19. The rate of hydrolysis increased and was
higher at pH 7.5 than at lower pH values. The average rate constant k2 was 0.006641 sec-1, and k1
was 0.0443 sec-1.
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Figure 20. Absorbance of RTZ complex monitored at 365 nm at a pH of 9.0 for 8 hours.
Equation (8) was used for the best fit curve after 100 minutes.
In Figure 20 the rate of product formation at a pH of 9.0 appears to increase, and the
induction period appears to be shorter than at lower pH’s. The average rate constant k2 was
0.003858 sec-1, and the rate constant k1 was 0.0459 sec-1.
The induction period for RTZ can also be related to the nucleation of the crystal and the
increase in the absorbance of the solution due to the precipitation caused by crystal growth. This
hydrolysis mechanism is similar to the kinetics of RIM complex, which may also exhibit the
crystal growth mechanism.29 In basic medium, hydrolysis was anticipated to follow a different
mechanism forming a ruthenium phosphate complex indicated by a dramatic change in the rate
constant values.
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All data were fit using equations (7) and (8) using the Graphical Analysis software. The
rate constants at various pH values for the hydrolysis of RTZ complex are displayed in Table 2.
Table 2. Average rate constants for two steps of hydrolysis of 0.045 M RTZ complex at
room temperature.

pH

k1 of all runs

Average k1

k2 of all runs

Average k2

(s-1)

(s-1)

(s-1)

(s-1)

0.0415
4.0

5.0

6.0

7.5

9.0

0.0182

0.003192
0.03463

0.003282

0.0442

0.003364

0.0241

0.004062

0.0484

0.03403

0.001444

0.0327

0.005281

0.0267

0.005385

0.0218

0.02391

0.006602

0.0231

0.006172

0.0343

0.004007

0.0475

0.0443

0.008431

0.0511

0.007484

0.0482

0.002408

0.0525
0.0372

0.0459

0.005714

0.003281

0.003601

0.006053

0.006641

0.003858

0.003812
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Table 2 clearly indicates that the rate of the hydrolysis of RTZ complex, which is
determined by k2, is highest in a pH 7.5 buffer solution. The rate constant of the first step of the
reaction k1 appeared to decrease from pH values of 4.0 to 6.0 but increased from pH values of
7.5 to 9.0. The rate constant of the second step k2 appeared to increase constantly from pH 4.0 to
7.5 and then decreased at a pH value of 9.0, which might be due to the interaction of the RTZ
complex with phosphate buffer at higher pH values.29 The values of k2 at different pH values are
illustrated in Figure 21.
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Figure 21. Comparison of rate constant k2 values of RTZ complex at various pH values.
3.3 1H-1,2,4-triazolium trans-tetrachlorobis (triazole) ruthenate(III) Complex (RTrz)
The absorbance spectra of the RTrz complex, shown in Figure 22, displays two
absorbance maxima, at 360 nm and at 420 nm. The peak at 420 nm remains constant over time,
but the peak at 360 nm shows a significant decrease of absorbance over time. Thus, the peak at
360 nm was utilized for studying the hydrolysis profiles of the RTrz complex.
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Figure 22. Absorbance profile of RTrz complex at a pH of 6.0 over time.
Hydrolysis studies of the RTrz complex were conducted at different pH levels over time
by observing the changes in absorbance at 360 nm. Figures 23 through 25 display absorbance
profiles of RTrz complex over time at pH levels of 4.0, 6.0, and 9.0.
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Figure 23. Absorbance of RTrz complex monitored at 360 nm at a pH of 4.0 for 7 hours
The curve in Figure 23 shows the rate of hydrolysis for RTrz complex at a pH of 4.0. All
the equations used for attaining the best fit for the curves obtained for the RIM, RTZ complexes
were utilized to fit the RTrz kinetic curve, but none gave an appropriate fit. Hence it was
hypothesized that the RTrz complex follows a different hydrolysis mechanism, and further
studies must be done to properly model the kinetics of the reaction.
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Figure 24. Absorbance of RTrz complex monitored at 360 nm at a pH of 6.0 for 5 hours.
The curve in Figure 24 displays a flat portion for times less than 75 minutes for the
hydrolysis of the RTrz complex in a pH of 6.0 buffer solution. After 75 minutes, the absorbance
displays a dramatic decrease. In acidic media, the solution was hazy but cleared within minutes,
resulting in a decrease in absorbance. The hydrolysis trend of RTrz complexes in acidic media
followed the opposite trend in absorbance than the other studied complexes in acidic pH. The
RTrz complex displayed a decrease in absorbance during hydrolysis, while the other complexes
exhibited an increase in absorbance.
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Figure 25. Absorbance of RTrz complex monitored at 360 nm at a pH of 9.0 for 5 hours.
Figure 25 shows the hydrolysis profile of the RTrz complex at a pH of 9.0. This curve
shows an increase in absorbance with time, which seems to indicate that a different species is
produced in basic solutions than acidic solutions. Initially, the solution was clear but became
turbid over time; this indicated the sensitivity of the RTrz complexes to pH conditions.
No kinetic rate constants were derived because proposed models based upon the
differential equations for the calculation of rate constants did not fit the data. The species
produced in the hydrolysis of the RTrz complex seem to be very sensitive to pH, showing
dramatically different patterns of absorbance at different pH values. Hence, to explain this
complexity, further studies should be done to understand the nucleation (induction period) and
crystal growth (increase or decrease of absorbance) steps.
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CHAPTER 4: CONCLUSIONS
The ruthenium complexes studied in this research exhibited different rates of hydrolysis
for formation of product as shown in Table 3. No data analysis was performed for RTrz because
no known model could fit the data.
In both the RIM and RTZ complexes, hydrolysis profiles show an induction period within
approximately the first 100 minutes. After the induction period, an increase in the hydrolysis rate
was observed in almost all solutions, regardless of the pH. The rate constant, k2, increases as pH
increases from 4.0 to 7.5 and then either decreases or shows a slight increase from pH 7.5 to 9.0
for all complexes in this study.
The mechanism of hydrolysis for the RTrz complex was different from the mechanism
exhibited by other complexes. The absorption curves changed dramatically at basic pH’s,
implying that a new species was formed in this reaction compared to that formed under acidic
conditions. The complex exhibits different hydrolysis patterns in acidic and basic solutions,
indicating that the species produced during the hydrolysis of the RTrz complex is dependent on
pH. Further studies such as NMR and LC-MS could help in resolving the kinetics of the RTrz
hydrolysis.
The increase or decrease in absorbance for these complexes was due to the increase or
decrease in turbidity in the solution. This turbidity was attributed to the precipitation occurring in
the solution. The mechanism for the precipitation reflects the crystal growth mechanism which
includes two phases. The first step is the nucleation, and the second step is the growth of the
crystal. Further studies must be conducted in order to elucidate the structure of the crystals
formed and elucidate the two steps more clearly.
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Table 3. Comparison of rate constants (k2) of the hydrolysis of RIM and RTZ complexes at
different pH values

Rate constant
(k2) in pH 4.0
(sec-1)

Rate constant
(k2) in pH 5.0
(sec-1)

Rate constant
(k2) in pH 6.0
(sec-1)

Rate constant
(k2) in pH 7.5
(sec-1)

Rate constant
(k2) in pH 9.0
(sec-1)

RIM complex

0.003510

0.004596

0.004544

0.006331

0.006693

RTZ complex

0.003281

0.003601

0.006053

0.006641

0.003858

The rate constant, k2, for the hydrolysis of the RIM complex was found to be higher for
higher pH levels. The hydrolysis of the RTZ complex was found to be highest in pH 7.5 buffer.
Hence these two complexes can be considered as good choice for controlling the rapid growing
cells in initial stages of cancer as the rate of active drug formation will be high at pH 7.5, which
is close to the pH of the blood stream, 7.4.19
The RTrz complex exhibited a rapid decrease in absorbance in higher pH levels,
indicating the possibility of rapid hydrolysis. The increase or decrease in absorbance correlates to
the pace of the hydrolysis reaction of the complexes, and the faster hydrolysis reaction indicates
faster decomposition of the Ru (III) form. Hence, it indicates the shelf life of this complex is
highly dependent upon the pH of the environment to which this complex is being exposed.
The higher the basicity of an azole ligand, the higher will be the energy of its excited state
and the more stable will be the Ru (III) state. All these factors affect the rate of hydrolysis.22,25
The increasing order of the basicity of the ligands in this study is as follows:
Triazole (pKa =2.2) < Thiazole (pKa =3.5) < Imidazole (pKa =6.99).22
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Because imidazole and thiazole are more basic, they have more electron donor character
than the triazole ligand. As the basicity of the ligand increases, the active form of ruthenium [Ru
(II)] becomes destabilized, thus requiring more time for its inactive form [Ru (III)] to be
reduced.22, 25 Thus, the mechanism of hydrolysis is dependent on the basicity of the ligands
complexed with the metal. More in-depth studies need to be done to characterize the steps of
hydrolysis more clearly.
Future Aspects:
A background spectrum of the phosphate buffer and a spectrum of the individual ligands,
and a comparison of these spectrums with that of the complexes, will be helpful in elucidating
the kinetics and behavior of these complexes at various pH values.
The hydrolysis studies, conducted at different temperatures and in different solvents, may
affect the stability of ruthenium complexes. NMR spectroscopy and HPLC –MS may be utilized
in the analysis of the hydrolysis in order to reveal the exact chemical structures of the
intermediate and product formed during the hydrolysis reactions. This study can be extended to
similar ligands like pyrazole, pyrimidine, phenanthrolines, and their derivatives in order to
further understand the effect of basicity of these ligands on the hydrolysis of these ruthenium
complexes. A future kinetic study of the ruthenium complexes bound to various purine and
pyrimidine bases of DNA at various pH levels may reveal important pharmacological parameters
such as the rate of drug release, the onset of action, and the duration of action of these
complexes. These results may help in better designing these complexes in the future.
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